The first rigorous human trial of tecovirimat—the only FDA-approved mpox treatment—reveals a striking disconnect between animal model predictions and human clinical reality. This finding challenges the regulatory pathway that approved the drug based solely on primate studies, highlighting fundamental gaps in translating infectious disease research from lab to clinic.
The international phase 3 trial enrolled 336 adults with active mpox lesions, randomizing them 2:1 to receive either tecovirimat or placebo for 14 days. By day 29, clinical resolution occurred in 83% of tecovirimat patients versus 84% receiving placebo—essentially identical outcomes with a hazard ratio of 0.98. Pain reduction, lesion healing time, and viral clearance showed similarly negligible differences between groups. Safety profiles were comparable, with no unexpected adverse events in either arm.
This null result carries profound implications for emergency preparedness and regulatory science. Tecovirimat received approval through the FDA's Animal Rule specifically because human efficacy trials were deemed unethical during smallpox's absence. Yet when mpox provided the natural experiment, the drug failed to demonstrate meaningful clinical benefit over supportive care alone. The finding suggests that either clade II mpox differs substantially from the primate models used for approval, or that tecovirimat's antiviral mechanism doesn't translate effectively to human pathophysiology. For clinicians managing mpox patients, this evidence undermines confidence in the primary therapeutic tool they've relied upon. More broadly, it raises questions about the Animal Rule pathway for approving countermeasures against bioterror agents when human testing opportunities eventually arise.